Providers should monitor weight trajectory , GI tolerability (nausea, vomiting, constipation) , signs of pancreatitis (persistent severe abdominal pain vomiting), gallbladder disease (RUQ pain, fever, jaundice), hydration/renal function when clinically indicated (risk of AKI with severe GI effects), blood pressure , and glucose metrics (especially if combined with insulin or sulfonylureas due to hypoglycemia risk)
The shortage of supply of GLP-1 therapies in South Africa is said to be caused by the rise in demand for their off-label use
Management strategies for vaginal health Over-the-counter vaginal moisturizers, used regularly rather than just during sexual activity, can maintain tissue hydration
If you are considering discontinuing GLP-1s, its essential to understand the potential consequences and how to navigate them